Insulatard (Insulin Human)

Insulin Human binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen synthesis, and suppress hepatic glucose production. This coordinated action lowers circulating glucose and supplies a steady insulin effect throughout the day.

The dose of Insulatard is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, type of diabetes, current glycaemic control, diet, activity level and other medications. Dosing adjustments are made according to regular blood‑glucose monitoring.

Insulatard may be used in pregnancy or while breastfeeding only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. The decision should be made by a healthcare professional familiar with the patient’s clinical situation.

To request Insulatard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Insulatard is a human insulin formulation with a relatively long duration of action, similar to other basal insulins such as insulin glargine or detemir. Compared with analogues, it may have a slightly different onset and peak profile, but it provides effective basal coverage when titrated appropriately.

Insulatard should be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen or shaken. Once in use, the vial can be kept at room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining solution should be discarded.

Insulatard is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to reduce the risk of lipodystrophy. Patients should follow the prescriber’s instructions regarding timing, dose and injection technique.

The most serious risks include severe hypoglycaemia, which can lead to seizures, loss of consciousness or injury, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention if a serious reaction occurs.

Insulatard is contraindicated in individuals with a known hypersensitivity to insulin human or any of the excipients in the formulation. It should also be avoided in patients experiencing severe hypoglycaemia until the condition is corrected, and used with caution in those with renal or hepatic impairment.